CAS NO: | 184475-55-6 |
生物活性 | Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally activeEGFRtyrosine kinaseinhibitor with anIC50of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50of 54 nM) and that blocks EGF-stimulatedEGFRautophosphorylation in tumor cells. Gefitinib hydrochloride also inducesautophagy. Gefitinib hydrochloride has antitumour activity[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Gefitinib (0.01-0.1 mM) results in increased phosphotyrosine load of the receptor, increased signalling to ERK and stimulation of proliferation and anchorage-independent growth, presumably by inducing EGFRvIII dimerisation in long-term exposure of EGFRvIII-expressing cells. On the other hand, gefitinib (1-2 mM) significantly decreases EGFRvIII phosphotyrosine load, EGFRvIII-mediated proliferation and anchorage-independent growth[1]. Gefitinib (ZD1839) inhibits the monolayer growth of these EGF-driven untransformed cells with IC50of 20 nM[2]. Gefitinib leads to an inhibition of CALU-3 and GLC82 cell proliferation, with an IC50of 2 μM[3]. | ||||||||||||||||
体内研究 (In Vivo) | Gefitinib (150 mg/kg, p.o.) in conbination with Metformin induces a significant reduction in tumor growth in nude mice bearing H1299 or CALU-3 GEF-R cells that are grown subcutaneously as tumor xenografts[3]. In irradiated rats, Gefitinib treatment augmentes lung inflammation, including inflammatory cell infiltration and pro-inflammatory cytokine expression, while Gefitinib treatment attenuates fibrotic lung remodeling due to the inhibition of lung fibroblast proliferation[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 483.36 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C22H25Cl2FN4O3 | ||||||||||||||||
CAS 号 | 184475-55-6 | ||||||||||||||||
中文名称 | 盐酸吉非替尼 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 6.25 mg/mL(12.93 mM;Need ultrasonic) DMSO : 0.227 mg/mL(0.47 mM;Need ultrasonic and warming) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |